Jamie A. Johansen 1, S. Marc Breedlove 1,2, Cynthia L. Jordan 1,2

1Neuroscience Program, 2Department of Psychology, Michigan State Universityjohanse8@msu.edu

Flutamide Rescues Transgenic Male Mice from the Toxic Effects of Over-expressing Wildtype Androgen Receptors in Skeletal Muscle Fibers

Introduction

Methods

• Spinal Bulbar Muscular Atrophy (SBMA) is a heritable X-linked, slowly progressive lower motor neuron disease characterized by adult onset of muscle weakness, atrophy, and loss of motoneurons.

• We created a transgenic mouse line in which a rat AR cDNA with a wildtype (Wt) number of glutamine residues (22) is over-expressed in muscle fibers using an HSA (human skeletal actin) promoter.

• Unexpectedly, tg male mice as adults show a disease phenotype typical of SBMA in humans.

• Very few transgenic males survive to weaning and recent evidence suggests that many tg males die on the day of birth.

• Given that tg females do not experience a similar mortality, we suspect that perinatal testosterone may cause many tg males to die as newborns.

• To examine whether blocking androgen action prenatally would protect our tg males from death on postnatal day 1, we treated pregnant dams with 5 mg flutamide/day on gestational days 15-20 .

• Construct: AR cDNA was subcloned from pCMVAR. cDNAs were ligated into the NotI site of pBSX-HSA.

• Prenatal Flutamide: 5 mg flutamide/day on gestational days 15-20 was given to pregnant dams.

• Behavioral Testing: Hang Test - Mice were placed on a wire grid, and then turned upside down, and the time to fall was measured in seconds. Paw Print Analysis – Front feet were painted with non-toxic acrylic red paint, and hind feet were painted with blue. Mice were then guided to walk along a strip of filter paper.

• Histology: Extensor Digitorum Longus (EDL) muscles were dissected from transgenic and wildtype males, cryostat sectioned at 10um, and stained for hematoxylin and eosin (H&E). Ventral roots were embedded in plastic and 1µm cross-sections were stained with toluidine blue.

• Prenatal flutamide treatment was successful in rescuing transgenic (tg) males from death.

• Tg males and their wildtype brothers were feminized, showing shorter ano-genital differences than untreated males.

• Tg males weighed less, and developed signs of SBMA as they reached adulthood.

• This included kyphosis, and a profound loss in muscle strength indicated by the hang test. Loss of muscle strength is an early indicator of the disease.

• However, stride length was not decreased suggesting that the disease in flutamide treated males had not progressed to late-stage SBMA.

• Tg males showed a reduction in the number of EDL muscle fibers, but no change in average fiber size.

• Tg males did not show a reduction in the number of L5 ventral root axons, also suggesting that the disease has not progressed to late-stage SBMA where motoneurons begin to die.

• No change in average axon size was seen.

Technical support was provided by Cindy Knaff, Chas Jensen, and Sandy Troxell.

These studies were funded by NIH NS-045195 (CLJ) and the MSU foundation (CLJ).

• This work demonstrates that prenatal flutamide can rescue tg males from death on postnatal day 1 but is not sufficient to prevent the eventual emergence of SBMA later in life.

• Flutamide treatment may delay the onset of SBMA, and disease progression may be slower in flutamide treated males.

• These results suggest that the wildtype AR, at sufficiently high levels, is toxic to muscle fibers.

• Ultimately, loss in muscle fiber function may lead to a loss of fibers, and eventually to a loss in motor neurons.

• Our results also suggest that SBMA and other motor neuron diseases may be myogenic in origin, contrary to the prevailing view.

Summary

Significance

Acknowledgments

Results: Flutamide rescues transgenic males.

Flutamide treated tg male mice are markedly smaller and exhibit kyphosis.

No loss in the number of size of ventral root axons is observed.

Figure 6. Left) There was no reduction in the number of L5 ventral root axons. Right) No change in average axon size was detected. Perhaps, if the disease was allowed to progress farther there would be a detectable difference in axon numbers, as seen in untreated tg males.

0100

200

300

400

500

600

700

800

900

1000

Num

ber

of A

xons

FLUT WTn=5

FLUT TGn=6

Axon Number

0

5

10

15

20

25

30

35

40

45

50

Ave

rage

Axo

n A

rea

(um

2)

FLUT WTn=5

FLUT TGn=6

Axon Size

Flutamide treated tg males have fewer muscle fibers, but no change in fiber size.

0

200

400

600

800

1000

1200

1400

1600

1800

Ave

rage

Fib

er A

rea

(um

2)

FLUT WTn=5

FLUT TGn=6

Fiber Size

0

200

400

600

800

1000

1200

Num

ber

of F

iber

s

FLUT WTn=5

FLUT TGn=6

Fiber Number

*

Figure 5. Left) FLUT tg mice show a significant reduction in the number of muscle fibers in the extensor digitorum longus (EDL) muscle compared to FLUT wt controls (p=.014). Right) No change in average fiber size was detected.

Figure 2. Left) FLUT tg males are approximately half the size of their flutamide treated wildtype (FLUT WT) brothers. Right) FLUT tg males exhibit kyhosis, or hunched back (arrow).

TG WT

Prenatal flutamide rescues transgenic (tg) males from death.

Figure 3. Left) FLUT tg males and FLUT wt males have ano-genital distances (AGD) similar to females at the age of weaning. Right) FLUT tg males show a significant reduction in body weight (p=.023) compared to wt brothers (FLUT WT) at sacrifice.

0

1

2

3

4

5

6

Str

ide

Len

gth

(cm

)

FLUT WTn=5

FLUT TGn=6

Stride Length

0

20

40

60

80

100

120

140

Tim

e (s

)

FLUT WTn=5

FLUT TGn=6

Hang Test

*

Figure 4. Left) FLUT tg males show a profound loss of motor function when tested with the Hang Test compared to FLUT wt brothers (p=.0003). This is similar to untreated tg males. Right) FLUT tg males do not show a loss in stride length, suggesting that the disease has not progressed as far in these males.

Flutamide treated tg males show a loss of motor function.

Flutamide treated tg males are feminized, but do develop symptoms of SBMA.

Survival

0

5

10

15

20

25

30

35

40

Per

cent

ali

ve a

t wea

ning

WT untreated

TG untreated

FLUT WT FLUT TG

Figure 1. Prenatal flutamide treatment in tg male mice was successful in rescuing males from death. Flutamide treated tg males (FLUT TG) had a higher rate of survival at weaning compared to untreated tg male mice.

0

5

10

15

20

25

30

FLUT WTn=5

FLUT TGn=6

Body Weight

*

Bod

y W

eigh

t (g)

0

.5

1

1.5

2

2.5

3

3.5

Ano

-gen

ital

dis

tanc

e (m

m)

FLUT WT male

FLUT TG male

FLUT WTfemale

FLUT TG female

AGD